Ouppatham Supasyndh 1 , Jian'an Wang 2 , Kudsia Hafeez 3 , Ying Zhang 3 , Jack Zhang 3 , Hiromi Rakugi 4 Show Affiliations »
Abstract
Show RCT »
Hide RCT «
OBJECTIVE: Systolic hypertension is common in elderly patients and remains a challenge to treat effectively. The efficacy and safety of sacubitril/valsartan (LCZ696 ), a first-in-class angiotensin receptor neprilysin inhibitor, vs. olmesartan was evaluated in elderly Asian patients (≥65 years) with systolic hypertension . METHODS: In this randomized, double-blind, 14-week study, patients initially received once-daily sacubitril/valsartan 100 mg or olmesartan 10 mg, increased to sacubitril/valsartan 200 mg or olmesartan 20 mg at week 4. At week 10, for patients with blood pressure (BP) >140/90 mm Hg, the doses were up-titrated to sacubitril/valsartan 400 mg or olmesartan 40 mg. The primary assessment was superiority of sacubitril/valsartan vs. olmesartan in reducing office mean sitting (ms) systolic BP (msSBP ) from baseline at week 10. Secondary efficacy assessments included changes from baseline in ms diastolic BP (msDBP), ms pulse pressure (msPP ), 24-hour mean ambulatory (ma) BP (maBP), and maPP at week 10; msBP and msPP at weeks 4 and 14. RESULTS: Overall, 588 patients were randomized (mean age, 70.7 years; baseline msBP, 160.3/84.9 mm Hg; msPP, 75.4 mm Hg). At week 10, sacubitril/valsartan provided superior msSBP reductions vs. olmesartan (22.71 vs. 16.11 mm Hg, respectively; P < 0.001); similarly, reductions from baseline in other BP and PP assessments were significantly greater with sacubitril/valsartan . At week 14, despite more patients requiring up-titration in the olmesartan group, msBP and msPP reductions from baseline were significantly greater with sacubitril/valsartan . Both treatments were generally well-tolerated . CONCLUSION: Sacubitril/valsartan is more effective than olmesartan in reducing BP in elderly Asian patients with systolic hypertension . © American Journal of Hypertension, Ltd 2017. All rights reserved. For Permissions, please email: journals.permissions@oup.com
RCT Entities: Population
Interventions
Outcomes
OBJECTIVE: Systolic hypertension is common in elderly patients and remains a challenge to treat effectively. The efficacy and safety of sacubitril /valsartan (LCZ696 ), a first-in-class angiotensin receptor neprilysin inhibitor, vs. olmesartan was evaluated in elderly Asian patients (≥65 years) with systolic hypertension . METHODS: In this randomized, double-blind, 14-week study, patients initially received once-daily sacubitril /valsartan 100 mg or olmesartan 10 mg, increased to sacubitril /valsartan 200 mg or olmesartan 20 mg at week 4. At week 10, for patients with blood pressure (BP) >140/90 mm Hg, the doses were up-titrated to sacubitril /valsartan 400 mg or olmesartan 40 mg. The primary assessment was superiority of sacubitril /valsartan vs. olmesartan in reducing office mean sitting (ms) systolic BP (msSBP) from baseline at week 10. Secondary efficacy assessments included changes from baseline in ms diastolic BP (msDBP), ms pulse pressure (msPP ), 24-hour mean ambulatory (ma) BP (maBP), and maPP at week 10; msBP and msPP at weeks 4 and 14. RESULTS: Overall, 588 patients were randomized (mean age, 70.7 years; baseline msBP, 160.3/84.9 mm Hg; msPP , 75.4 mm Hg). At week 10, sacubitril /valsartan provided superior msSBP reductions vs. olmesartan (22.71 vs. 16.11 mm Hg, respectively; P < 0.001); similarly, reductions from baseline in other BP and PP assessments were significantly greater with sacubitril /valsartan . At week 14, despite more patients requiring up-titration in the olmesartan group, msBP and msPP reductions from baseline were significantly greater with sacubitril /valsartan . Both treatments were generally well-tolerated. CONCLUSION: Sacubitril /valsartan is more effective than olmesartan in reducing BP in elderly Asian patients with systolic hypertension . © American Journal of Hypertension , Ltd 2017. All rights reserved. For Permissions, please email: journals.permissions@oup.com
Entities: Chemical
Disease
Gene
Species
Keywords:
Asian; angiotensin receptor neprilysin inhibitor; blood pressure; elderly; hypertension; pulse pressure; sacubitril/valsartan; systolic hypertension
Mesh： See more »
Substances： See more »
Year: 2017
PMID： 28992296 DOI： 10.1093/ajh/hpx111
Source DB: PubMed Journal: Am J Hypertens ISSN： 0895-7061 Impact factor: 2.689